ARCT News and Press, Arcturus Therapeutics Ltd. From 01/07/21

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were skyrocketing 40.9% higher as of 3:10 p.m. EST on Thursday. The huge gain came after Wells Fargo analyst Jim Birchenough initiated coverage on the stock with an overweight rating. He also set a $118 price target -- a premium of 139%...

Arcturus Therapeutics (NASDAQ: ARCT) soared 299% in 2020 as it advanced its coronavirus vaccine candidate into human trials. Investors were betting that the investigational mRNA vaccine would demonstrate efficacy to rival similar ones developed by bigger rivals Pfizer (NYSE: P...

Arcturus Therapeutics (NASDAQ: ARCT) stock has made some investors rich lately while causing headaches for others -- all depending on when they opened their positions. Those who bought shares last January and are still holding them are sitting on notional returns of more than ...

The FDA has allowed Arcturus Therapeutics' (ARCT) Investigational New Drug ((IND)) application for the Phase 2 clinical study of its vaccine candidate ARCT-021 following review of data from the Phase 1/2 study. The Phase 2 study will enroll 600 participants, with 450 receiving ARCT-021 and 15...

Phase 2 study to be conducted in the U.S. and Singapore, and will evaluate both single dose and two dose priming regimens of ARCT-021 in up to 600 participants Anticipate interim Phase 2 data in early 2021; targeting global Phase 3 study start in Q2 2021 which could allow appl...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A drifting New Year's Eve stock market kicked into bullish mode in the last two hours of trading Thursday, helping the S&P 500 and the Do...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

In an investor update on Monday, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported early-stage clinical trial results for its coronavirus vaccine candidate. The company also said that the Singapore Health Sciences Authority had granted approval to begin a phase 2 study of that ...

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were plunging 53.7% as of 11:16 a.m. EST on Tuesday. The huge decline came after the biotech reported data from an early-stage clinical study of COVID-19 vaccine candidate ARCT-021. Investors had high hopes that a single do...

Gainers: Tenax Therapeutics (TENX) +132%, Regional Health Properties (RHE) +38%, IRIDEX (IRIX) +22%, INmune Bio (INMB) +17%, Mirum Pharmaceuticals (MIRM) +8%.Losers: Arcturus Therapeutics (ARCT) -53%, Actinium Pharmaceuticals (ATNM) -24%, Alpine Immune ...